Endoscopic transnasal dacryocystorhinostomy -long-term results

Summary

Endoscopic dacryocystorhinostomy (DCR) was successfully performed in 40 patients, with four patients having bilateral surgery. Follow-up data were obtained on 43/44 eyes using clinical notes and a patient questionnaire. Range of follow up was 1–46 months, with an average of 18 months (in nine patients follow up was at least 3 years). Epiphora was successfully relieved in 86% of patients and there was no evidence of a recurrence of nasolacrimal obstruction in the long term. Endoscopic DCR is a relatively quick and simple procedure with low morbidity, and as such is suitable for day case surgery. Satisfactory long-term results make endoscopic DCR an alternative to external DCR as primary surgical treatment for nasolacrimal duct obstruction. In cases of failed external DCR, or when epiphora is iatrogenic following surgery to the lateral nasal wall, a transnasal endoscopic approach is probably the treatment of choice.     

正常犬气管内高位留置支架的实验研究

目的探讨气管内高位留置支架的安全性及影响因素。方法24只实验犬平均分为3组,气管内高位留置支架。A组:支架上缘平声门下缘,B组:支架上缘在声门下5mm,C组:支架上缘在声门下15mm。术后观察实验犬有无呼吸困难、咳嗽、喘息、呼吸急促,有无吞咽困难和发声困难。术后1周、1个月、3个月、6个月各组分别处死2只实验犬,处死前螺旋CT检查,观察支架移位情况。观察标本病理改变,比较不同时间增生组织厚度,并进行方差分析。结果实验犬均无急性呼吸、吞咽或发声困难发生,均有轻、中度咳嗽,3～5天后缓解。A组1只犬术后5天因持续腹泻死亡,C组1只犬术后21天死亡,尸检未见喉、气管及食管异常。各组实验犬术后发声和进食正常。8只犬(A组3只,B组2只,C组3只)术后8～12周左右出现喘鸣、呼吸费力,CT提示气管腔狭窄,其中5只在3个月时处死,另3只继续饲养,呼吸困难、喘鸣6个月逐渐缓解。复查时支架均有向下移位,各组移位距离无统计学差异(P>0.05),1周、1个月、3个月、6个月时移位距离无统计学差异(P>0.05)。支架留置后不同时间组织增生厚度存在明显差异(P<0.05),1周、1个月、3个月、6个月时增生组织厚度分别为(0.84±0.21)mm、(1.26±0.33)mm、(8.61±1.73)mm、(2.58±0.87)mm。3个月时增生厚度大于1周、1个月、6个月时增生厚度(P<0.05)。结论①声门下气管内留置支架是安全的,不会引起急性呼吸困难和窒息,不影响进食和发声功能;②气管内高位留置支架容易发生轻度下移,支架移位发生于1周内,1周后支架位置相对稳定;③支架留置后3个月内组织增生随时间增长而逐渐加重,6个月时有减轻趋势。     

Endoscopic drill-assisted dacryocystorhinostomy

Summary

With the introduction of endoscopes for endonasal surgery, there have been an increasing number of endonasal dacryocystorhinostomies (DCR) performed. The advantages of the endonasal approach include the avoidance of an external facial scar and reduced risk of damage to the medial canthal ligament. We described our experience with the use of the Hall Osteon drill for endoscopic DCR. This procedure has been found to be technically reliable giving satisfactory post-operative results in 16 patients suffering from nasol-acrimal duct obstruction. The follow up was up to 12 months with a mean of 5 months. Three patients who had residual post-operative epiphora were considered as failures. There were no major complications and minor complications included one case of periorbital ecchymosis, one unretrieved silicone tube and a minor vestibule abrasion. The preliminary results suggest that the endoscopic drill-assisted DCR could offer a reliable treatment in patients with epiphora due to nasolacrimal duct obstruction.     

Multiple stenting of refractory pancreatic duct strictures in severe chronic pancreatitis: long-term results

BACKGROUND AND STUDY AIMS: Dominant pancreatic duct strictures located in the head of the pancreas in patients with severe chronic pancreatitis are often managed by endoscopic placement of a single plastic stent. Patients with refractory strictures after prolonged stenting require repeated stent replacement or surgical pancreaticojejunostomy. Placement of multiple plastic stents has proved effective in managing postoperative biliary strictures. The aim of this study was to investigate the feasibility, efficacy, and long-term results of multiple stenting of refractory pancreatic strictures in severe chronic pancreatitis. PATIENTS AND METHODS: 19 patients with severe chronic pancreatitis (16 men, three women; mean age 45 years) and with a single pancreatic stent through a refractory dominant stricture in the pancreatic head underwent the following protocol: (i) removal of the single pancreatic stent; (ii) balloon dilation of the stricture; (iii) insertion of the maximum number of stents allowed by the stricture tightness and the pancreatic duct diameter; and (iv) removal of stents after 6 to 12 months. RESULTS: The median number of stents placed through the major or minor papilla was 3, with diameters ranging from 8.5 to 11.5 Fr and length from 4 to 7 cm. Only one patient (5.5 %) had persistent stricture after multiple stenting. During a mean follow-up of 38 months after removal, 84 % of patients were asymptomatic, and 10.5 % had symptomatic stricture recurrence. No major complications were recorded. CONCLUSION: Endoscopic multiple stenting of dominant pancreatic duct strictures in chronic pancreatitis is a feasible and safe technique. Multiple pancreatic stenting is promising in obtaining persistent stricture dilation on long-term follow-up in the setting of severe chronic pancreatitis.     

胆道支架和鼻胆管引流在腹腔镜胆总管探查术后一期缝合中的应用

目的 对比胆道支架和鼻胆管引流在腹腔镜胆总管探查术（LCBDE）后一期缝合中的临床疗效。方法 回顾性分析2016年8月－2021年1月在该院行内镜逆行胰胆管造影术（ERCP）取石失败的74例患者的临床资料，分为支架引流组（n = 38）和鼻胆管引流组（n = 36）。支架引流组ERCP取石失败后放置胆道支架引流，鼻胆管引流组ERCP取石失败后放置鼻胆管引流，两组患者均行腹腔镜胆总管切开取石一期缝合术。比较两组患者手术时间、术后住院时间、术后并发症发生率、术后肠道功能恢复时间、术后胆总管结石复发率和住院时间。结果 两组患者胆管缝合方式、手术时间、术中出血量、术后并发症总发生率和住院费用比较，差异均无统计学意义（P > 0.05）。鼻胆管引流组术后胆瘘发生率明显低于支架引流组，住院时间明显短于支架引流组，术后肠道功能恢复时间明显长于支架引流组，术后总补液量多于支架引流组，差异均有统计学意义（P < 0.05）。结论 ERCP取石失败后放置鼻胆管引流，可降低LCBDE术后一期缝合的胆瘘发生率，缩短住院时间，但放置胆道支架引流患者肠道功能恢复更快，补液量更少。因此，在临床操作中，应根据患者具体情况，选择相应的个体化引流方式。     

Application of resonance metallic stents for malignant ureteral obstruction

Abstract

Purpose: To determine the effectiveness of the Resonance metallic stent in treating malignant ureteral obstruction (MUO) and clarify the risk factors that lead to stent failure.

Material and methods: We retrospectively identified and analyzed the records of patients who had MUO and underwent placement of Resonance metallic stents from November 2014 to June 2017 in our hospital. Stent failure was defined as unexpected interventions including stent exchange, need of percutaneous nephrostomies (PCN) or ureterocutaneostomy.

Results: A total of 22 stents were placed in 14 patients with MUO. The median follow-up was 145?days (4.8?months) and the maximum duration of stenting was 21.3?months. The technique success rate was 100%. Two patients experienced early postoperative increasing creatinine with oliguria but only one of them failed to achieve primary patency. The overall success rate was 90% (9/10).

Conclusion: Resonance metallic stent is a safe and effective treatment for MUO and can maintain durable patency over 12?months. Preoperative urinary tract infection (UTI) and tumor invasion into the bladder are considered as risk factors of stent blockage and failure. Early postoperative elevated creatinine oliguria, suggestive with intrarenal and prerenal disease, should not be deemed to be stent failure.     

Endoscopic removal of biliary self-expandable metallic stents: a prospective study

BACKGROUND AND STUDY AIMS: The transpapillary endoscopic insertion of self-expandable metallic stents (SEMSs) has been widely used for the palliation of unresectable malignant biliary obstruction. We attempted the endoscopic removal of malfunctioning SEMSs. The aim of this study was to assess the feasibility and safety of the endoscopic removal of SEMSs by comparing the results between removal of covered and uncovered SEMSs. PATIENTS AND METHODS: 30 patients with a malfunctioning biliary SEMS prospectively underwent an attempt at endoscopic removal of the biliary SEMS over a 2-year period. Removal of the malfunctioning SEMS was done with a therapeutic duodenoscope (ED-450XT5 or TJF-240), using a rat-tooth forceps. Of the 30 SEMS used, 22 were silicone-covered Wallstents, while eight were uncovered SEMSs including five uncovered Wallstents and three Zilver stents. The time for an attempt at each endoscopic removal was limited to 15 minutes in a single endoscopic procedure session. RESULTS: The covered SEMSs were easily removed in 19 out of 22 patients (86.4 %), whereas none of the eight uncovered SEMSs (0 %) could be removed. The only factor predicting successful stent removal was the presence of a stent covering ( P = 0.000). There was no morbidity or mortality related to endoscopic removal of malfunctioning stents. CONCLUSIONS: In contrast to uncovered biliary SEMSs, in most cases malfunctioning covered biliary SEMSs can be easily and safely removed endoscopically using a rat-tooth forceps.     

Long-term outcome after pancreatic stenting in severe chronic pancreatitis

BACKGROUND AND STUDY AIMS: Although it has been proved that pancreatic stenting is effective in the symptomatic management of severe chronic pancreatitis, long-term outcomes after stent removal have not been fully evaluated. PATIENTS AND METHODS: A total of 100 patients (75 men, 25 women; median age 49) with severe chronic pancreatitis and pancreatic duct strictures were successfully treated for pancreatic pain using polyethylene pancreatic stents and were followed up for at least 1 year after stent removal. The stents were exchanged "on demand" (in cases of recurrence of pain) and a definitive stent removal was attempted on the basis of clinical and endoscopic findings. Clinical variables were retrospectively assessed as potential predictors of re-stenting. RESULTS: The etiology of the chronic pancreatitis was alcoholic (77 %), idiopathic (18 %), or hereditary (5 %). Patients were followed up for a median period of 69 months (range 14 - 163 months) after study entry, including a median period of 27 months (range 12 - 126 months) after stent removal. The median duration of pancreatic stenting before stent removal was 23 months (range 2 - 134 months). After attempted definitive stent removal, 30 patients (30 %) required re-stenting within the first year of follow-up, at a median time of 5.5 months after stent removal (range 1 - 12 months), while in 70 patients (70 %) pain control remained adequate during that period. By the end of the follow-up period a total of 38 patients had required re-stenting and four ultimately underwent pancreaticojejunostomy. Pancreas divisum was the only factor significantly associated with a higher risk of re-stenting (P = 0.002). CONCLUSIONS: The majority (70 %) of patients with severe chronic pancreatitis who respond to pancreatic stenting maintain this response after definitive stent removal. However, a significantly higher re-stenting rate was observed in patients with chronic pancreatitis and pancreas divisum.     

硬质支气管镜联合电子支气管镜直视下置入气管支架治疗食管癌致中央气道狭窄的临床疗效

目的 探讨硬质支气管镜联合电子支气管镜直视下置入金属或硅酮气管支架治疗食管癌侵犯气管致中央气道狭窄的临床应用价值。方法 回顾性分析该院呼吸与危重症医学科2019年10月-2021年7月诊治的13例食管癌侵犯气管致中央气道中重度狭窄患者的临床资料,所有患者均在全身麻醉肌松下插入硬质支气管镜,在电子支气管镜实时引导下行金属支架或硅酮支架置入治疗,观察其临床效果。结果 13例患者成功置入金属支架7枚,硅酮支架6枚（1枚直筒型,5枚Y型）。支架置入后,患者卡氏功能状态（KPS）评分、经皮动脉血氧分压（PaO2）和经皮动脉血氧饱和度（SpO2）明显高于支架置入前（P <0.05）;气管狭窄程度较支架置入前明显改善,气促分级、呼吸困难博格评分和二氧化碳分压（PCO2）明显低于支架置入前（P <0.05）;金属支架组和硅酮支架组术后近期并发症、远期并发症、3个月生存率和6个月生存率比较,差异均无统计学意义（P> 0.05）。结论 在硬质支气管镜联合电子支气管镜直视下置入气管支架治疗食管癌所致的中央气道狭窄,安全可行,能迅速解除气管狭窄,近期效果显著,为患者后续治疗提供了保障。     

Spiral nitinol biliary stents in a porcine model: evaluation of the potential for use in benign strictures.

BACKGROUND AND STUDY AIMS: Self-expanding spiral nitinol stents are potentially removable and may be useful in the treatment of benign strictures. We evaluated the histologic response to stent placement and technical aspects of their placement and removal in a porcine model. METHODS: Nine animals were studied. Stents were placed above the papilla in six surviving animals. After intervals of one, two or three months cholangiography and attempted stent removal was performed. Four animals were then sacrificed acutely with their stent in place, and two were sacrificed after a one-month healing interval. The results of placement, follow-up cholangiography and histology are reported. RESULTS: Cholangiography and stent placement succeeded in 26 of 27 and 11 of 16 attempts, respectively. Three placement failures were attributed to stent/duct size disparity or a faulty release mechanism, resulting in stent kinking and/or duct twisting. Among the successfully deployed stents, two animals developed strictures where stents traversed bifurcations and one exhibited partial luminal compromise by tissue entrapment between coils. Fluoroscopically guided removal was successful in two of five stents positioned above the papilla. Histology was non-specific but minimally changed in those given a one-month healing interval after removal. Others exhibited moderate inflammation, fibrosis and an intramural abscess at sites of induced stricture. CONCLUSIONS: Spiral metal stents for the treatment of benign strictures remain experimental. Care must be taken to deploy them in bile ducts of adequate diameter and endoscopic removal is not yet demonstrably reliable and safe.     

Efficacy of a novel large-cell Niti-S stent with a slim delivery system for hilar biliary obstruction: a preliminary study

ObjectivesThe large-cell Niti-S stent is useful for multiple stenting in patients with malignant hilar biliary obstruction (MHBO). Recently, a novel uncovered self-expandable metallic stent (USEMS) (a Niti-S large-cell SR slim delivery system) was developed. In this study, we aimed to evaluate the efficacy of this USEMS slim delivery system in MHBO patients.Materials and methodsOutcomes related to USEMS placement, the clinical course, and the period to recurrent biliary obstruction (RBO) were evaluated in MHBO patients who received multiple USEMSs with the Niti-S large-cell SR slim delivery system.ResultsTwenty-two MHBO patients underwent the placement of multiple USEMSs, including the novel slim-delivery stent. Six patients had a past history of upper gastrointestinal reconstruction (Billroth I: 1, Billroth II: 4, Roux-en-Y: 1). The number of USEMSs placed in each patient was 2-6. Three procedures were reinterventions. The new slim delivery system was placed as the first stent in ten patients and as an additional stent in the remaining patients. Seven patients were drained using only Niti-S large-cell SR slim delivery stents. The technical and clinical success rates were both 100%.ConclusionsPlacing multiple USEMSs in patients with a past history of abdominal surgery or in reintervention is difficult. Although difficult cases were included in this study, stent-in-stent placement with the novel Niti-S large-cell SR slim delivery system was useful in treating MHBO patients. In addition, this novel stent might be the first choice for MHBO patients.

KEY MESSAGES

• Endoscopic multistenting for MHBO is challenging. In addition, reintervention or multistenting for MHBO patients with a past history of abdominal surgery becomes more difficult.
• The novel Niti-S large-cell SR slim delivery USEMS is useful as an additional stent because the delivery system is thin and suitable for a 0.025 guidewire. In addition, the novel stent is of the braided type and has a large mesh. Therefore, the novel stent is expected to have strong radial force and can be used as the first SEMS.
• The Niti-S large-cell SR slim delivery stent is long enough to be used in patients with upper gastrointestinal reconstruction. Although this study included patients with reintervention or a past history of upper gastrointestinal reconstruction, the technical success rate of multiple stenting for MHBO patients was 100%. The slim-delivery stent might overcome several difficulties of endoscopic multistenting.

     

Rationale and design: Impact of intravascular ultrasound guidance on long-term clinical outcomes of everolimus-eluting stents in long coronary lesions

BackgroundAlthough the use of drug-eluting stents (DESs) in patients with coronary artery disease has contributed to a significant reduction in in-stent restenosis and repeat revascularization, treating diffuse long lesions using DESs remains challenging due to the high rates of in-stent restenosis and stent thrombosis. Intravascular ultrasound (IVUS) provides tomographic images of coronary vascular structure and is useful for evaluating lesion morphology and stent optimization during percutaneous coronary intervention. However, it remains controversial whether IVUS guidance in DES implantation for long coronary lesions could reduce adverse clinical outcomes.HypothesisWe hypothesize that the long-term clinical outcomes of IVUS-guided DES implantation would be superior to those of angiography-guided DES implantation in a subset of patients with long coronary lesions.Study designThis study is a randomized, prospective, multi-center trial comparing the long-term clinical outcomes of IVUS-guided and angiography-guided everolimus-eluting stent implantation in patients with long coronary lesions (implanted stent ≥ 28 mm in length). The primary end point is a composite of major adverse cardiac events, including cardiac death, target lesion-related myocardial infarction, or target lesion revascularization at 1 year following intervention. A total of 1,400 patients will be required to be enrolled according to sample size calculations.ConclusionThis study will test the hypothesis that IVUS guidance improves long-term clinical outcomes in patients treated with everolimus-eluting stents for long coronary lesions compared with angiographic guidance.     

Technical failure of biliary metal stent deployment in a series of 116 applications.

Biliary metal stents are thought to offer improved long-term palliation of malignant biliary obstruction due to a lower incidence of migration and clogging. Placement of these stents is technically more complicated than that of plastic endoprostheses and requires two experienced physicians. We report the incidence and reasons for apparent malfunction of expandable metal stent deployment (Wallstents and Strecker stents). In 116 applications of 82 Wallstents (endoscopic approach: n = 33, transhepatic approach: n = 49), we observed 19 cases of stent malfunction due to technical problems of stent delivery. In 13 cases (15.8%), the restraining membrane of the Wallstent could not be retracted sufficiently to deliver the stent. There were 6 (17.6%) failures in 34 cases of Strecker stent deployment. In 3 cases, we noted difficult balloon removal, including avulsion of the balloon catheter shaft within the endoscope during attempted balloon removal in one case. In one case, the Strecker stent could only be released partially, requiring subsequent endoscopic extraction. In two patients, only partial expansion of one end of the Strecker stent could be achieved. Given the significant malfunction rate of expandable metal stents during stent delivery, further improvements in the delivery system of the metal stents are required.     

食管癌完全性梗阻导管法再通支架置入术

目的 探讨食管癌晚期食管完全性梗阻时支架的置入方法。方法 首先采用导管 导丝法使梗阻再通，后依次扩张、支架置入。结果 共完成食管癌完全性梗阻支架置入16例。结论 导管法再通支架置入术是治疗食管癌完全性梗阻的有效方法。     

超声心动图诊断儿童马凡综合征

目的 观察儿童马凡综合征（MFS）患者的超声心动图表现。方法 回顾性分析临床疑诊MFS的59例患儿的影像学及临床检查资料,观察其超声心动图表现。结果 12例诊断为MFS,6例诊断为潜在MFS,其中11例存在家族史,7例为散发病例。上述18例中,4例存在主动脉窦部增宽,11例存在主动脉窦部扩张,1例合并主动脉瓣轻度反流,2例合并肺动脉窦部扩张;8例二尖瓣受累,5例二尖瓣脱垂并中—重度反流,5例三尖瓣受累;1例同时存在二尖瓣及三尖瓣脱垂而接受二尖瓣成形术;1例合并室间隔缺损,接受室间隔缺损修补术。结论 儿童MFS中,以主动脉窦部增宽或扩张最为常见,可合并二尖瓣脱垂;超声心动图检查有助于早期诊断和及时干预儿童MFS。     

内镜下不同方式治疗难治性腐蚀性食管狭窄的临床研究（附3例报告）

目的 探讨内镜下不同方式治疗难治性腐蚀性食管狭窄的临床疗效。方法 回顾性分析3例分别行内镜探条扩张术、支架植入术及内镜下推进式放射状切开术（EPRD）治疗难治性腐蚀性食管狭窄患者的临床资料。结果 经反复内镜治疗后，3例患者均获得良好的治疗效果，术中及术后均未出现大出血和穿孔等严重并发症，并且随着治疗次数增多，狭窄缓解时间越长，吞咽困难改善也越明显。3种治疗方式中，支架植入术对吞咽困难的改善效果最明显。结论 内镜探条扩张术、支架植入术及EPRD治疗难治性食管狭窄均是安全可行且有效的方法。     

Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction

Expandable metal biliary stents are reserved for patients with unresectable malignant biliary obstruction. Occasionally, these stents may cause complications necessitating removal. We describe successful endoscopic removal of a biliary Wallstent one year after insertion in a patient who initially underwent placement of an expandable metal biliary stent for presumed biliary malignancy. The stent was removed after a stent related bleeding duodenal ulcer formed.     

Risk factors for post-endoscopic retrograde cholangiopancreatography cholangitis in patients with hepatic alveolar echinococcosis—an observational study

BackgroundHepatic alveolar echinococcosis (HAE) is considered to be one of the most deadly chronic parasitic diseases in the world. We have shown that the incidence of cholangitis in patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) was increased significantly. On this finding, we carried out, a preliminary study on the risk factors for cholangitis after ERCP.AimsTo retrospectively detect the risk factors for post-ERCP cholangitis in patients with biliary tract affected by HAE.MethodsThe study included data from 51 cases of AE who had undergone therapeutic ERCP between January 2015 and December 2019. Demographic and treatment data were extracted from the medical records, and the association between potential risk factors and the development of post-ERCP cholangitis was evaluated using a collected database.ResultsThere were five cases of mild cholangitis after ERCP (Tokyo criteria), and no moderate or severe cholangitis occurred. The incidence rate of cholangitis after ERCP was 9.8%. Univariate analysis showed hilar bile duct stenosis (p = .016), endoscopic retrograde biliary drainage (p = .007), a stent diameter ≥8.5 Fr (p = .000) and single stent implantation (p = .010) were risk factors for post -ERCP cholangitis. All cases of cholangitis improved under conservative treatment.ConclusionPatients with hilar bile duct compression or endoscopic retrograde biliary drainage appeared to be more likely to develop post-ERCP cholangitis. The number and diameter of biliary stents may influence post-ERCP cholangitis. Sample size and clinical heterogeneity are two insurmountable difficulties, and a larger sample size needs to be collected to verify the risk factors for screening.

KEY MESSAGES

• Many studies reported the post-ERCP complications in patients with hepatic alveolar echinococcosis and found that the incidence of post-ERCP cholangitis was significantly high. Therefore, we conducted a preliminary study on the risk factors of postoperative cholangitis in patients who underwent ERCP.
• The incidence rate of cholangitis after ERCP was 9.8%. We found that hilar bile duct stenosis, and endoscopic retrograde biliary drainage, were risk factors for cholangitis, and stent diameter and the number of stent implantation may influence the incidence rate of cholangitis after ERCP.
• Sample size and clinical heterogeneity are two insurmountable difficulties, and a larger sample size needs to be collected to verify the risk factors of screening.

     

髂动脉闭塞内膜下再通治疗与覆膜支架的应用

目的 探讨应用内膜下再通和覆膜支架植入术治疗髂动脉硬化闭塞病变的方法和疗效.方法 5例伴有严重缺血症状的髂动脉完全闭塞病变患者,动脉闭塞长度2.5～12.0 cm.采用顺行途径(经右肱动脉穿刺3例,经对侧股动脉穿刺2例)对闭塞段血管行意向性内膜下途径再通,用直径8 mm球囊对内膜下通道扩张成形并植入镍钛合金覆膜支架,共植入覆膜支架6枚,另在1处狭窄病变植入覆膜支架1枚,1处长段闭塞病变覆膜支架远段和另1处髂动脉狭窄病变中各植入裸支架1枚.结果 内膜下再通操作全部获技术成功,无并发症出现.覆膜支架置放后血管腔内形态良好,血流通畅.临床症状消失或明显改善.患肢踝臂指数(ABI)平均值由0.40±0.32上升至0.89±0.15.近中期随访无症状复发.结论 动脉内膜下再通术联合覆膜支架植入术治疗髂动脉硬化闭塞病变安全、有效,近中期疗效良好.     

国产内支架治疗前列腺增生

目的　探讨国产前列腺内支架治疗前列腺增生引起排尿困难的临床疗效。方法　 3 2例前列腺增生引起排尿困难的患者 ,置入 3 5枚前列腺内支架。支架均为国产镍钛记忆合金编织而成。结果　 3 2例均一次治疗成功 ,2 8例置入支架后立即自行排尿 ,3例因前列腺增生过大 ,前列腺尿道部过长 ,置入 1个支架 ,排尿仍有困难 ,再次置入第 2个支架后 ,立即自行排尿 ,1例伴有糖尿病的患者 ,置入支架 1周后排尿困难未改善 ,而进行外科手术治疗。 2 8例生活质量积分 0～ 3分 ,19例术后随访 6～ 18个月 ,国际前列腺症状评分 (I PSS)术前 2 7.5 9± 4.11,术后 6.93± 3 .76(P <0 .0 0 1) ,最大尿流率术前 (1.79± 3 .89)ml/s,术后 (14 .2 5± 3 .65 )ml/s(P <0 .0 0 1)。结论　前列腺支架治疗前列腺增生引起的排尿困难是可靠的。